Welcome to the 
(Video) Library

Tyler, a person with Alagille syndrome

REAL PEOPLE TAKING LIVMARLI

Hear from real patients and their families as they share their unique experiences—life before diagnosis, challenges before starting LIVMARLI, and the difference LIVMARLI is making in their lives.*

*Not all patients taking LIVMARLI will have the same experiences.

Videos>Meet Finley
NOW PLAYING

Meet Finley

Finley experienced multiple symptoms for months before finally getting diagnosed and starting LIVMARLI.

[00:00:00]

[music]

Dani: Really careful.

Jackson: You can try it by yourself.

Dani: Good job. You got to do one at a time.

Jay: My name's Jay.

Dani: I'm Dani. We have two beautiful boys: Jackson, who's four, and Finley, who's one.

Jay: Jackson's just [00:00:30] a mover and a shaker. He is a ball of energy. He's just always on the move, but he's creative, he's energetic.

Dani: Finley's personality is a lot more mellow. He really enjoys reading books together, listening to music, and he really likes to see how things work. Jackson's pregnancy, super easy. No complications, no NICU stay, no hospital stay. It was a really straightforward pregnancy. Not with Finn [00:01:00] though. Not with Finn. Good job, Finley.

Jackson: [unintelligible 00:01:05].

Dani: We were very excited to add another little baby to our family. So we got pregnant with Finn. Something that was supposed to be joyous ended up turning into not that.

Jay: In that 20-week ultrasound where they look at all of the anatomy of the fetus, they couldn't see one of the chambers of his heart. That was just the start of what was going [00:01:30] on. So we went back for another ultrasound because he was measuring small. He was measuring, at that time, in the 11th percentile. We went back and he was measuring in the ninth percentile and that's when they found what's called an echogenic bowel. We were referred to see a high-risk pregnancy doctor every couple weeks.

Dani: Finley was born a month early, so he spent the first 2 weeks of his life in the NICU. His liver numbers were really high, but they weren't [00:02:00] super concerned yet. They were just waiting to see if those liver numbers started to track down. That's when we heard the term “bronze baby syndrome.” This is what they call when they knew that something was wrong with Finley's liver. There's this one particular photo of Jay and Finley. He was holding him up over his shoulder.

Jay: You can see the fear in that picture and that's one that will forever stick out to me, is one moment where [00:02:30] it set in that like, "Okay, we're not going home right away. When we do go home, it's not going to be what we thought it was. It's not going to be what it was like when we had Jackson."

Dani: We weren't out of the woods in this one. We knew, at this time, there was something wrong. He was still jaundiced, he wasn't gaining weight, and it was a very isolating experience. It was during COVID. I, of course, refused to leave my newborn son, so I spent a lot [00:03:00] of my time there.

Jay: It was a lot. It was hard, a lot to process.

Dani: They did a lot of different tests. They did echo outside and that's when they discovered that he had pulmonary stenosis. They wanted to do a liver biopsy to rule out biliary atresia, and really look at the bile ducts and see how they were growing. They kind of [00:03:30] told us, "We don't really have an answer," but that's when we really first heard of Alagille syndrome and that it might be something that Finley has. [00:04:00]

I'm supposed to protect him, and I feel like the mutation is my fault, even though, logically, I know it's not. It was a brand new mutation; it doesn't run in either of our families, but I couldn't do my job as a mother to make sure he was born healthy. That's why I do a lot of research into what Alagille syndrome is, what other families go through. [00:04:30]

Jay: Some of the symptoms that we were experiencing after diagnosis were the continued poor weight gain and being undersized, jaundice levels in his skin. We were starting to see signs of him itching.

Dani: The itch was one of the bigger pieces in that early diagnosis that we missed then, but now we understand it because a lot of the signs that our doctor told us to look out for: the rubbing of the face on your shoulder if you're holding him up [00:05:00] here, rubbing of the feet or belly, when they're trying to do tummy time. Then the scratching of the eyes or grabbing at the ears, all those are normal hunger cues, sleepy cues. Really trying to figure out what's the difference between the two. Looking back at it now, we definitely see that most of the signs were itching and not necessarily related to typical newborn behavior.

Finley, in the evening, his itch would be pretty bad [00:05:30]. He was waking up every 2 to 3 hours, well before that 6-hour mark that our doctor told us that hydroxyzine would last. The itch impacted Finley's life. That period of time is a blur from how exhausted we all were. Jackson slept through the night, so it didn't seem to disrupt him. But it did disrupt our lives though when we were awake because Jackson wanted to play, and Finley was really tired. Mommy and daddy were really tired. It was a pretty rough, dark time. [00:06:00]

Jackson: Do you want to try? Do you want to try and [unintelligible 00:06:04]? [unintelligible 00:06:06]. Oh, look at that.

[laughter]

Jackson: [unintelligible 00:06:12] he's going to do it. He's going to do it. No. [unintelligible 00:06:15] try it by yourself. You can try it by yourself.

Jay: Our doctor had introduced LIVMARLI as a possible option for Finley pretty early on after diagnosis. They work with a number of families in the area that have kids with Alagille, [00:06:30] and they've just seen it really help with the itch in those children.

Dani: For me, why I wanted to get Finley on LIVMARLI was the itch. Seeing it wake him up in the middle of the night, seeing him try to play with Jackson, and eat his food, and do all those things, and just to see those little hands grabbing at the eyes, grabbing at the ankles and feet. Just seeing how much itching was really impacting him.

Jay: Finley started on LIVMARLI shortly after his first birthday, [00:07:00] when we had our follow-up with his GI doctor. Around that 4-week mark, we were really happy to see that he was reaching for his legs and feet less than what we would see when he would itch. He just had more time to be Finley and it's really awesome.

Dani: It was nice to see him be able to focus on something else outside the itch. We want him to thrive, be a child who isn't impacted by the itch through liver disease. We just want him to be a normal 1-year-old child. Our doctors shared that there could be [00:07:30] some side effects for Finley after taking LIVMARLI, but we didn't really see any of those. We didn't see the diarrhea, no vomiting. We didn't really see any...

Jay: ...changes in his vitamin levels. All remained stable.

Dani: None of the things that our doctors did share that we could potentially see on LIVMARLI, we didn't experience anything like that.

[music]

Jay: I think we've really tried to just see how much [00:08:00] has changed in the time he's been on it with the itch subsiding and going down that it just made doing these things more enjoyable for him. We get to celebrate those moments and look at how much fun he's having without seeing him grabbing at his knees, grabbing at his ears like we used to see. It's hard to quantify it, but you just see him being a kid and having fun with his brother, and doing the slide and playing at the park. It just warms your heart, makes me happy. It makes us smile.

Dani: Just because he has been [00:08:30] dealt a certain hand in life, that doesn't mean his rare disease defines it. Finley is smart. He's happy and he's healthy, or stable in his own way.

Jay: The ultimate goal would be for people to just understand that Finley is just like any other kid and that he may have some differences that make him look a little smaller and look a little different, but he's still capable of doing what anybody else is. [00:09:00] We want to be a voice for Finley and other kids with Alagille. We want people to understand.

Dani: I feel like you might not use the word fortunate a lot in the rare diseases world, but we are really fortunate to have Alagille Alliance. Not too many rare diseases have this group of folks together that help provide the scientific research, help give you information and connect with other families who are also going through Alagille with you. We feel very fortunate that we're part of such a [00:09:30] well-known and...

Jay: ...tight community.

Dani: Yes.

Female Speaker:

INDICATION

LIVMARLI is indicated for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) 3 months of age and older.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Liver Test Abnormalities: Patients enrolled in clinical trials had abnormal liver tests at baseline. In the main clinical trial, [00:10:00] treatment-emergent elevations or worsening of liver tests (ALT, AST or T/DB) relative to baseline were observed. Obtain baseline liver tests and monitor during treatment. Dose reduction or treatment interruption may be considered if abnormalities occur in the absence of other causes. For persistent or recurrent liver test abnormalities, consider treatment discontinuation. Discontinue permanently if a patient progresses to portal hypertension or experiences a hepatic decompensation [00:10:30] event.

GI Adverse Reactions: Diarrhea, abdominal pain and vomiting were reported as the most common adverse reactions. If diarrhea, abdominal pain and/or vomiting occur and no other etiologies are found, consider reducing the dose or interrupting LIVMARLI. For diarrhea or vomiting, monitor for dehydration and treat promptly. Consider interrupting LIVMARLI dosing if a patient experiences persistent diarrhea or has diarrhea with accompanying signs and symptoms [00:11:00] such as bloody stool, vomiting, dehydration requiring treatment, or fever. Restart LIVMARLI at 190 mcg/kg/day when diarrhea, abdominal pain or vomiting resolve, and increase the dose as tolerated. If they recur upon re-challenge, consider stopping LIVMARLI treatment.

Fat-Soluble Vitamin Deficiency: ALGS patients can have fat-soluble vitamin (FSV) deficiency (vitamins A, D, E, and K) at baseline, [00:11:30] and LIVMARLI may affect absorption of FSV. In the main clinical trial, treatment emergent FSV deficiency was reported in 3 (10%) patients during 48 weeks of treatment. Obtain baseline serum levels and monitor during treatment, along with any clinical manifestations. Supplement if deficiency is observed. Consider discontinuing LIVMARLI if FSV deficiency persists or worsens despite adequate FSV supplementation.

ADVERSE REACTIONS

The most [00:12:00] common adverse reactions (≥5%) are diarrhea, abdominal pain, vomiting, fat-soluble vitamin deficiency, liver test abnormalities, gastrointestinal bleeding and bone fractures.

DRUG INTERACTIONS

Administer bile acid binding resins at least 4 hours before or 4 hours after administration of LIVMARLI.
A decrease in the absorption of OATP2B1 substrates (eg, statins) due to OATP2B1 inhibition by LIVMARLI [00:12:30] in the GI tract cannot be ruled out. Consider monitoring the drug effects of OATP2B1 substrates as needed.

DOSING INFORMATION

LIVMARLI should be taken 30 minutes before a meal in the morning. The provided oral dosing dispenser must be used to accurately measure the dose. Any remaining LIVMARLI should be discarded 100 days after first opening the bottle.

[music]

[00:13:00]

[00:13:15] [END OF AUDIO]

Root Out
Excess Bile

Learn how LIVMARLI—the first FDA-approved treatment for cholestatic pruritus in Alagille syndrome—battles bile acid buildup.1

See How LIVMARLI Works

Encourage patients to download the Itch✓ app to help them track symptom patterns over time and generate customized reports to share at appointments.

Check Out the Itch✓ App

Mirum Access Plus assists both you and your patients at every turn, helping you navigate the payer approval process—and beyond—with ease.

Learn More About
Mirum Access Plus
Collapse icon

Important Safety Information

Contraindications

LIVMARLI is contraindicated in patients with prior or active hepatic decompensation events (eg, variceal hemorrhage, ascites, or hepatic encephalopathy).

Warnings and Precautions

Hepatotoxicity: LIVMARLI treatment is associated with a potential for drug-induced liver injury. In the Alagille syndrome trial, treatment-emergent elevations of liver tests or worsening of liver tests occurred.

Obtain baseline liver tests and monitor during treatment. Liver-related adverse reactions and physical signs of hepatic decompensation should also be monitored. Dose reduction or treatment interruption may be considered if abnormalities occur in the absence of other causes. For persistent or recurrent liver test abnormalities, consider treatment discontinuation. Permanently discontinue LIVMARLI if a patient experiences the following: persistent or recurrent liver test abnormalities, clinical hepatitis upon rechallenge, or a hepatic decompensation event.

GI Adverse Reactions: Diarrhea and abdominal pain were reported as the most common adverse reactions. Monitor for dehydration and treat promptly. Consider reducing the dosage or interrupting dosing if a patient experiences persistent diarrhea or has diarrhea with bloody stool, vomiting, dehydration requiring treatment, or fever.

Fat-Soluble Vitamin Deficiency: Patients can have fat-soluble vitamin (FSV) deficiency (vitamins A, D, E, and K) at baseline, and LIVMARLI may adversely affect absorption of FSV. If bone fractures or bleeding occur, consider interrupting LIVMARLI and supplement with FSVs. LIVMARLI can be restarted once FSV deficiency is corrected and maintained at corrected levels.

Adverse Reactions

The most common adverse reactions are diarrhea, abdominal pain, vomiting, FSV deficiency, liver test abnormalities, and bone fractures.

Drug Interactions

Administer bile acid binding resins at least 4 hours before or 4 hours after administration of LIVMARLI. A decrease in the absorption of OATP2B1 substrates (eg, statins) due to OATP2B1 inhibition by LIVMARLI in the GI tract cannot be ruled out. Consider monitoring the drug effects of OATP2B1 substrates as needed.

Dosing Information

LIVMARLI should be taken 30 minutes before a meal. The provided oral dosing dispenser must be used to accurately measure the dose. Any remaining LIVMARLI should be discarded 100 days after first opening the bottle.